HIV chemoprophylaxis in U.S. up 738% in recent 3-year period

DURBAN, SOUTH AFRICA – The number of Americans using oral emtricitabine/tenofovir (Truvada) to prevent HIV infection jumped by 738% during a recent 3-year period since the drug’s 2012 marketing...
Source: Ob.Gyn. News - Category: OBGYN Source Type: research